SARS-CoV-2 viral load dynamics in immunocompromised critically ill patients on remdesivir treatment.
COVID-19
Remdesivir
SARS-CoV-2
immunosuppression
viral load
Journal
Multidisciplinary respiratory medicine
ISSN: 1828-695X
Titre abrégé: Multidiscip Respir Med
Pays: Italy
ID NLM: 101477642
Informations de publication
Date de publication:
12 Jan 2022
12 Jan 2022
Historique:
received:
09
12
2021
accepted:
12
04
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
2
6
2022
Statut:
epublish
Résumé
The relationship between SARS-CoV-2 quantitative viral load and risk of disease progression, morbidity such as long- COVID or mortality in immunosuppressed, remains largely undefined in COVID-19 patients. Critically ill immunosuppressed patients potentially benefit from remdesivir treatment because of the prolonged course of their infection. Four critically ill immunocompromised patients and the impact of remdesivir on viral dynamics in lower respiratory samples were studied. Bronchoalveolar lavage (BAL) samples were assessed to measure SARS-CoV-2 quantitative viral load using real-time PCR. Corresponding plasma levels of remdesivir and its metabolite GS-441524 were determined. Mean virus load of 39.74 x 10
Identifiants
pubmed: 35646346
doi: 10.4081/mrm.2022.825
pmc: PMC9134301
doi:
Types de publication
Journal Article
Langues
eng
Pagination
825Informations de copyright
©Copyright: the Author(s).
Références
Viruses. 2021 Feb 15;13(2):
pubmed: 33672005
Viruses. 2021 May 22;13(6):
pubmed: 34067381
Nat Commun. 2020 Dec 14;11(1):6385
pubmed: 33318491
Nature. 2020 Sep;585(7824):273-276
pubmed: 32516797
Clin Microbiol Infect. 2021 Jun;27(6):917.e1-917.e4
pubmed: 33705849
J Antimicrob Chemother. 2021 Feb 11;76(3):825-827
pubmed: 33251541
Nat Commun. 2020 Oct 30;11(1):5493
pubmed: 33127906
Clin Epidemiol Glob Health. 2021 Jan-Mar;9:123-127
pubmed: 32838064